LKT Labs

Biochemicals for Life Science Research

Cyclovirobuxine D

Cyclovirobuxine D

Product ID C9711
Cas No. 860-79-7
Purity ≥97%
Product Unit SizeCostQuantityStock
25 mg $128.00 In stock
100 mg $318.00 In stock
500 mg $1,086.00 In stock
Bulk Quote

Quicklinks

Description

Cyclovirobuxine D is originally found in Buxus and displays cardioprotective and anticancer activities. Cyclovirobuxine inhibits the viability of breast cancer cells, inhibiting phosphorylation of Akt and mTOR and inducing autophagy. This compound also shows benefit in the treatment of heart failure but may prolong the QT interval through inhibition of human ether-a-go-go-related (hERG) K+ channel currents. Additionally, cyclovirobuxine D decreases infarct size and venous thrombus size in animal models of myocardial ischemia.

Product Info

Cas No.

860-79-7
Purity

≥97%
Formula

C26H46N2O
Formula Wt.

402.66
IUPAC Name

C26H46N2O
Synonym

Bebuxine, Cyclovirobuxine
Melting Point

219-224°C
Appearance

White crystal

Shipping and Storage

Store Temp

4°C
Ship Temp

Ambient

Downloads

MSDS

C9711 MSDS PDF
Info Sheet

C9711 Info Sheet PDF

References

Lu J, Sun D, Gao S, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. PMID: 24758922.

Yu B, Fang TH, Lü GH, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77. PMID: 21575690.

Zhao J, Wang Q, Xu J, et al. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells. Eur J Pharmacol. 2011 Jun 25;660(2-3):259-67. PMID: 21497594.

Hu D, Liu X, Wang Y, et al. Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. Eur J Pharmacol. 2007 Aug 13;569(1-2):103-9. PMID: 17555743.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • T2833

    1-Thio-β-D-glucose Tetraacetate

    Imaging agent; Maillard reaction inhibitor.

    ≥98%
  • G1849

    Gemifloxacin Mesylate

    Fluoroquinolone; bacterial DNA gyrase inhibitor...

    ≥98%
  • P6800

    Pravastatin Lactone

    Statin; HMG-CoA reductase inhibitor.

    ≥98%
  • P3465

    Piperine

    Alkaloid found in black and long peppers; TRPV1...

    ≥95%
  • I9060

    IWP-2

    PORCN inhibitor.

    ≥98%
  • N3422

    Nifekalant Hydrochloride

    Voltage-gated K+ channel blocker.

    ≥98%
  • N4974

    NMS-E628

    ALK and Ros1 inhibitor, Trk antagonist.

    ≥98%
  • N3584

    Nivalenol

    Trichothecene mycotoxin produced by Fusarium; p...

    ≥98%
  • O4531

    Oligomycin A

    Macrolide; F1F0 ATP synthase inhibitor.

    ≥97%, TLC, HPLC
  • G5320

    GNF-2

    Abl inhibitor.

    ≥98%
  • J766160

    JTE907

    Selective Cannabinoid receptor 2(CB2) inverse a...

    ≥98%
  • S5868

    Sorafenib

    c-Raf, Ret, VEGFR2 inhibitor, potential STAT3/5...

    ≥98%
  • B5074

    BMS-599626

    EGFR, VEGFR inhibitor.

    ≥98%
  • T1655

    Tenoxicam Impurity 1

    Tenoxicam impurity

    ≥98%
  • C104761

    CCT-196969

    pan-Raf inhibitor.

    ≥98%
  • P0398

    Pazufloxacin Methanesulfonate

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • H0003

    H89

    PKA inhibitor, potential ROCK, S6K1, MSK1, PKB ...

    ≥98%
  • F3205

    Fibrinogen γ-chain Dodecapeptide

    Platelet substitute, peptide; GP IIb/IIIa activ...

    ≥95%
  • C086007

    CC-671

    TTK/CLK2 inhibitor.

    ≥98%
  • A5170

    Amrinone

    Pyridine; PDE3 inhibitor.

    ≥98%